Medline Inc. Class A common stock
MDLN
$44.28
+0.64%
Medline Inc. is the largest medical-surgical products and supply chain solutions provider in the United States. The company's identity is defined by its significant scale, extensive product portfolio, and prime vendor relationships with major health systems.
MDLN
Medline Inc. Class A common stock
$44.28
Related headlines
Investment Opinion: Should I buy MDLN Today?
Based on a synthesis of the fundamental data, valuation, and market sentiment, the objective assessment for Medline (MDLN) is a 'Hold' with a 'Buy' bias for risk-tolerant investors. The company's foundational strengths as a market leader with strong growth are clear, and analyst sentiment is overwhelmingly positive. However, the recent compression in profitability metrics and regulatory headline risk create near-term uncertainty. Investors should await clearer signs of margin stabilization and the resolution of the FDA product concern before establishing or adding to a full position.
Sign up to view all
MDLN 12-Month Price Forecast
The analysis yields a neutral stance with medium confidence. The company's strong fundamentals and growth are counterbalanced by clear near-term headwinds in profitability and product safety. The high probability base case suggests limited upside from the current price without a clear catalyst for margin improvement.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Medline Inc. Class A common stock's 12-month outlook, with a consensus price target around $57.56 and implied upside of +30.0% versus the current price.
Average Target
$57.56
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$35 - $58
Analyst target range
Wall Street analyst sentiment is overwhelmingly positive. Recent institutional ratings from ten major firms include seven 'Buy' or 'Outperform' ratings, two 'Overweight' ratings, and one 'Equal Weight' rating, with no sell ratings. A consensus of seven analysts estimates average EPS of $2.39 and average revenue of $41.06 billion for the coming period.
Bulls vs Bears: MDLN Investment Factors
Medline presents a compelling case as the dominant player in a stable healthcare sector, backed by strong revenue growth and analyst confidence. However, recent margin compression, regulatory scrutiny, and the inherent volatility of a new public stock introduce significant near-term risks. The investment thesis hinges on the company's ability to stabilize profitability post-IPO.
Bullish
- Strong Market Position: Largest US medical-surgical supplier with extensive product portfolio and prime vendor relationships.
- Robust Revenue Growth: Q4 2025 revenue grew 21.9% YoY, indicating strong demand and market share gains.
- Healthy Financial Liquidity: Current ratio of 4.29 and strong free cash flow of $1.74B provide operational flexibility.
- Overwhelming Analyst Support: No sell ratings; 9 out of 10 analysts rate it Buy/Outperform/Overweight.
Bearish
- Recent Profitability Pressures: Q4 net margin fell to 2.3% from ~4.5% in prior quarters, raising concerns.
- Post-IPO Volatility: Stock has seen a -17.8% max drawdown, typical of recent IPOs and creating uncertainty.
- Regulatory & Product Risk: FDA flagged safety risks for homecare beds, potentially impacting brand and sales.
- Moderate Financial Leverage: Debt-to-equity of 1.17 indicates reliance on debt financing.
MDLN Technical Analysis
Overall Assessment: The stock has shown significant volatility since its IPO in December 2025, with a 52-week range of $34.89 to $50.876. The current price of $44.50 represents a 5.95% gain over the last three months, significantly outperforming the S&P 500's -4.63% change, indicating strong relative strength in the medium term.
Short-term Performance: Over the past month, the stock has declined by 6.34%, underperforming the broader market's -5.25% drop. However, it has gained 4.41% from the previous close of $42.62, suggesting recent positive momentum. The price has recovered from a recent low near $41 in mid-March.
Current Position: The current price of $44.50 is approximately 31.4% above the 52-week low and 12.5% below the 52-week high, positioning it in the upper-mid range. The stock has experienced a maximum drawdown of -17.84% from its peak, reflecting the volatility typical of a recent IPO.
Beta
—
—
Max Drawdown
-17.8%
Largest decline past year
52-Week Range
$35-$51
Price range past year
Annual Return
+8.0%
Cumulative gain past year
| Period | MDLN Return | S&P 500 |
|---|---|---|
| 1m | -0.2% | -3.6% |
| 3m | +9.0% | -4.0% |
| 6m | +8.0% | -2.0% |
| 1y | +8.0% | +16.2% |
| ytd | +9.0% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MDLN Fundamental Analysis
Revenue & Profitability: The company reported Q4 2025 revenue of $7.787 billion, representing a 21.9% year-over-year growth. However, net income for the quarter was $180 million, resulting in a net margin of 2.3%, which is significantly lower than the 4.5%-4.8% margins seen in prior quarters of 2025, indicating potential profitability pressures.
Financial Health: The debt-to-equity ratio stands at 1.17, indicating a moderate level of leverage. The current ratio is strong at 4.29, suggesting ample liquidity to cover short-term obligations. Free cash flow for the trailing twelve months is a healthy $1.744 billion.
Operational Efficiency: Return on Equity (ROE) is 10.79%, while Return on Assets (ROA) is 3.66%. The latest quarterly operating margin was 5.46%, down from levels above 8% in earlier 2025 quarters, pointing to potential operational cost challenges or investment phases.
Quarterly Revenue
$7.8B
2025-12
Revenue YoY Growth
+0.21%
YoY Comparison
Gross Margin
+0.24%
Latest Quarter
Free Cash Flow
$1.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MDLN Overvalued?
Valuation Level: Given the company's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 29.43, while the forward P/E is 26.83 based on analyst estimates. The Price-to-Sales ratio is 1.20, and the EV/EBITDA is 15.34.
Peer Comparison: Data not available for direct industry average comparisons. However, the forward P/E of 26.8 suggests the market is pricing in future growth expectations. The PEG ratio is negative at -4.97, which is typically not meaningful for comparison as it results from estimated growth rates.
PE
29.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 24x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
Medline's risk profile is moderate to high, primarily driven by its status as a recent IPO. Financial risks include a noticeable decline in quarterly profitability margins, with the Q4 2025 net margin dropping to 2.3% from levels above 4.5% earlier in the year. This could signal integration costs, competitive pressures, or investment spending that may persist. The debt-to-equity ratio of 1.17 indicates a moderate level of financial leverage that could pressure earnings if interest rates rise.
Operational and regulatory risks are highlighted by the recent FDA warning regarding safety fire risks in its homecare beds. While the product was not removed, such events can damage brand reputation, lead to litigation, and result in costly recalls or design changes. Furthermore, as a company with over 90% domestic revenue, it is highly exposed to U.S. healthcare policy changes and reimbursement pressures.
Market risks are evident in the stock's technical performance, with a maximum drawdown of -17.8% since its IPO peak, reflecting the typical volatility and price discovery phase for new listings. The lack of a long trading history makes it difficult to assess its true beta and resilience during broader market downturns.
FAQ
Key risks include: 1) Recent profitability compression, with Q4 net margin dropping significantly. 2) Regulatory risk from an FDA safety warning on homecare beds. 3) Post-IPO stock price volatility, with a -17.8% max drawdown already experienced. 4) Moderate financial leverage with a debt-to-equity ratio of 1.17.
The 12-month outlook is mixed. The base case (50% probability) sees the stock trading between $44.50 and its 52-week high of $50.88, assuming it meets analyst EPS estimates of $2.39. The bull case (30%) could see it exceed $50.88 on margin recovery, while the bear case (20%) could see it retest lows near $34.89 if risks materialize.
Based on current metrics, MDLN appears fairly valued. Its forward P/E of 26.8 and Price-to-Sales ratio of 1.2 are not excessive for a market-leading healthcare company with double-digit revenue growth. It is not deeply undervalued, but also not significantly overvalued compared to its own fundamentals and growth trajectory.
MDLN is a good long-term investment candidate due to its market leadership and strong revenue growth (21.9% YoY in Q4). However, it is not a low-risk buy at the moment. Recent margin pressure (net margin fell to 2.3%) and post-IPO volatility suggest investors should consider a 'Hold and monitor' approach, awaiting more stable quarterly results before committing new capital.
MDLN is more suitable for a long-term investment horizon. Its business model as a critical healthcare supplier is durable, but the near-term challenges (IPO volatility, margin questions) require patience. Short-term traders may be challenged by the stock's volatility, while long-term investors can potentially benefit from the company's scale and market consolidation over time.